Digital Diagnostics, formerly known as IDx, is a leading AI diagnostics company that develops clinically-aligned autonomous algorithms that detect disease in medical images.
Digital Diagnostics is on a mission to transform the quality, accessibility, and affordability of healthcare.
Digital Diagnostics was founded in 2010 by Michael Abramoff. The commpany is based in Coralville, Iowa, with offices in Chicago, Austin and Boston.
Digital Diagnostics developed developed a unique, patented biomarker-based approach to build AI algorithms that perform cognitively complex tasks. These algorithms are integrated into easy-to-use systems that can make instantaneous clinical decisions in which the computer makes the medical decision.
Digital Diagnostics and its flagship product IDx-DR, an autonomous AI system FDA-authorized to diagnose diabetic retinopathy and diabetic macular edema, has proven that intelligent diagnostic platforms can be used safely, efficiently and equitably to improve patient outcomes.
Digital Diagnostics works closely with patient advocacy groups, federal regulators, and other quality of care and ethics-focused stakeholders to enable the adoption of autonomous AI.
Digital Diagnostics is backed KKR, 8VC, Optum Ventures, Alpha Edison, Cedar Pine, Heritage Provider Network, Leach Capital, Kinderhook, OSF Ventures, Gundersen Health System, University of Iowa, and others. The company raised $75M in Series B round on Aug 23, 2022. This brings Digital Diagnostics' total funding to $139.6M to date.